5-year Outcomes Following a HIFU Focal Therapy Study Demonstrate Impressive Disease Control & Low Side Effect Profiles
July 11, 2018
Charlotte, NC (PR Newswire) July 05, 2018 – SonaCare Medical, the leading developer and manufacturer of high intensity focused ultrasound (HIFU) technologies, is pleased to report 5-year outcomes from a multicenter study following focal therapy treatment with its Sonablate technology of 625 medium to high-risk clinically significant non-metastatic prostate cancer patients.
With a median five-year follow-up, failure free survival at one, three, and five years was 99%, 92%, and 88% respectively, equivalent to that achieved with surgery. Metastasis-free, cancer-specific, and overall survival at five years was 98%, 100%, and 99% respectively. The study additionally reports that 98% of men maintained pad-free urinary continence after their procedure and 85% maintained erectile function, both material improvements over that seen with surgery and radiation therapy.
The study concluded that failure free survival with HIFU can be equivalent to that of surgery but with a side effect profile far more beneficial to the patient’s quality of life post-procedure. A recent report from the U.K. on 1,000 patients who underwent a radical prostatectomy found maintenance of pad-free continence at only 65%. This suggests that focal HIFU therapy can result in a 97% reduction in the number of men who require pads post-procedure when compared to surgery; ancillary data suggests a similar magnitude reduction in erectile dysfunction with focal HIFU compared to surgery.
“Focal HIFU is a major shift in treating men with early prostate cancer. Our study shows that cancer control in the medium term is very good and importantly, men can expect a low-risk of side effects such as incontinence and erection problems,” states Prof. Hashim Ahmed, Chair of Urology at Imperial College London and contributing author to this study. “All men who are suitable for focal HIFU should be told about this treatment option so they might consider it as an alternative to radical prostatectomy or radiotherapy.”
“This is a landmark study in the treatment of medium to high-risk prostate cancer authored by one of the leading clinical research groups in the field,” adds Dr. Mark Carol, CEO of SonaCare Medical. “It encompasses the largest focal treatment patient population to date followed for the longest period of time. Until now, otherwise healthy men with prostate cancer faced the prospect of leaving the hospital after treatment with their cancer treated but with a compromised quality of life. This study shows it is possible to achieve whole-gland equivalent cancer control rates without the concomitant side effect profile of whole gland treatments. Now, otherwise healthy men with prostate cancer can leave the hospital post focal HIFU treatment with their cancer under control yet still healthy. They can even return back to work and activities of daily living the very next day instead of having to wait the weeks required with surgery. This represents a remarkable achievement and a treatment option that should be made available to all men with prostate cancer!”